Get the latest news, insights, and market updates on ORMP (Oramed Pharmaceuticals Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
ORAMED PHARMACEUTICALS INC. DECLARES DIVIDEND DISTRIBUTION OF COMMON STOCK PURCHASE RIGHTS
The Board of Directors of Oramed Pharmaceuticals Inc. (the "Company") announced today that it has unanimously adopted a Rights Agreement, dated November 17, 2025 (the "Rights Plan"), by and between the Company and Continental Stock Transfer & Trust Company, as rights agent, and declared a dividend of one common stock purchase right (a "Right") on each outstanding share of its common stock, par value $0.012 per share (the "Common Stock"), of the Company. The Rights are designed to assure that all Nov 17, 2025 - $ORMP
Oramed: Q3 Earnings Snapshot
NEW YORK (AP) — Oramed Pharmaceuticals Inc. ORMP) on Thursday reported net income of $48.4 million in its third quarter. The New York-based company said it had profit of $1.13 per share. Nov 13, 2025 - $ORMP
Scilex Holding Company Announces the Completion of the First Tranche of the Oramed Pharmaceuticals, Inc. Warrant Repurchase
PALO ALTO, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that it has repurchased 3,130,000 warrants to purchase shares of Scilex common stock having an exercise price of $0.01 per share (“Warrants Oct 1, 2025 - $ORMP
Oramed: Q2 Earnings Snapshot
NEW YORK (AP) — Oramed Pharmaceuticals Inc. ORMP) on Thursday reported net income of $13.3 million in its second quarter. On a per-share basis, the New York-based company said it had profit of 31 cents. Aug 14, 2025 - $ORMP
With Substantial Liquidity, ORMP Has Generated Gains & Income From Investment Portfolio
By M. Marin NASDAQ:ORMP READ THE FULL ORMP RESEARCH REPORT Company maintains substantial liquidity Oramed Pharmaceuticals (NASDAQ:ORMP) had cash of $74.5 million at the end of March 2025, up from $54.4 million at year-end 2024. ORMP is leveraging its balance sheet to make investments in other early stage companies, in addition to advancing its strategy to move its assets forward. One of the Jul 28, 2025 - $ORMP
Oramed: Q1 Earnings Snapshot
NEW YORK (AP) — Oramed Pharmaceuticals Inc. ORMP) on Thursday reported a loss of $7.6 million in its first quarter. On a per-share basis, the New York-based company said it had a loss of 19 cents. May 15, 2025 - $ORMP
Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical
Oramed Pharmaceuticals Inc. ("Oramed" or the "Company"), (Nasdaq: ORMP) (TASE: ORMP), a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection, announced today that it has successfully closed a strategic investment in Alpha Tau Medical Ltd. (Nasdaq: DRTS), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®. Through a registered direct offering (the "offering"), an affiliate of Oramed purchased approximately 14.1 mil Apr 28, 2025 - $ORMP
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple